Text Size

Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts

Lallemand F., Schmitt M., Bourges J.-L., Gurny R., Benita S., Garrigue J.-S.


  • 2017
  • European Journal of Pharmaceutics and Biopharmaceutics
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology

    Drug Delivery

  • Affiliations

    Santen SAS, Evry, France; Department of Ophthalmology, Paris Descartes School of Medicine, Assistance Publique-Hôpitaux de Paris, Cochin-Hôtel-Dieu Hospital, Université Sorbonne Paris Cité, Paris, France; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, Israel

Related Publications

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Correlation between gene expression and clinical scores in vernal keratoconjunctivitis

Leonardi A, Cavarzeran F, Rosani U, Righetti G, Garrigue JS, Brun P.


Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials

Leonardi A, Doan S, Aragona P,  Amrane M, Ismail D, Montero J, Németh J, Bremond-Gignac D


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022